Targeting ARID1A-Deficient Cancers: An Immune-Metabolic Perspective

卷:12

Review

关键词: ARID1A LOSS;    MUTATIONS;    CHECKPOINT;    PATHWAYS;    DRIVE;    AXIS;   

DOI  :  10.3390/cells12060952

来源: SCIE

【 摘 要 】

Epigenetic remodeling and metabolic reprogramming, two well-known cancer hallmarks, are highly intertwined. In addition to their abilities to confer cancer cell growth advantage, these alterations play a critical role in dynamically shaping the tumor microenvironment and antitumor immunity. Recent studies point toward the interplay between epigenetic regulation and metabolic rewiring as a potentially targetable Achilles' heel in cancer. In this review, we explore the key metabolic mechanisms that underpin the immunomodulatory role of AT-rich interaction domain 1A (ARID1A), the most frequently mutated epigenetic regulator across human cancers. We will summarize the recent advances in targeting ARID1A-deficient cancers by harnessing immune-metabolic vulnerability elicited by ARID1A deficiency to stimulate antitumor immune response, and ultimately, to improve patient outcome.